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Abstract. Dextran was covalently coupled to neutral unilamellar liposomes. Dextran 
conjugated liposomes were cleared from the circulation at a much slower rate than 
unconjugated liposomes. The uptake of dextran conjugated liposomes by liver and spleen was 
also decreased. The amount of dextran on the surface of liposomes was found to be a 
determining factor for their stability in circulation. Dextran conjugated liposomes therefore 
may be a more effective way of controlled drug release. 
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Introduction 
 
Liposomes are becoming increasingly important as carriers of biologically important 
molecules in living system (Tyrell et al., 1976; Papahadjopoulos, 1978; Gregoriadis, 
1980; Roerdink et al., 1981). Introduction of a specific sugar onto the liposomal surface 
either by specific glycolipids or by coupling p-aminophenyl glycosides helps in directing 
the liposome towards different cell types of liver (Ghosh and Bachhawat, 1980; Ghosh 
et al., 1981a, 1982). Glycoside-bearing liposomes have been used to deliver therapeutic 
substances in galactosamine induced hepatitis (Ghosh et al., 1981b). Although drugs in 
general usually must quantitatively arrive at their target, drug-bearing liposomes, 
however, which have extremely long half-lives in the circulation could enhance the 
treatment of some of the diseases involving lack of serum factors or can serve as 
intravascular sustained release of antitumor drugs and other agents. Dextran has long 
been used as drug carrier to confer greater chemical and biological stability to dextran- 
drug complex (Molteni, 1979). Dextran remains in the blood stream for periods of time 
proportional to its molecular weight. In this paper we have conjugated dextran with 
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liposomes and have shown that such dextran conjugated liposomes can serve the dual 
purpose of extending the duration of drugs in the circulation considerably and of 
protecting the drug from the hostile environment. 
 
 
Materials and methods  
 
Chemicals 
 
Egg lecithin, cholesterol and phosphatidylethanolamine were obtained from CSIR 
Centre for Biochemicals, New Delhi. Sepharose-6B, bovine γ-globulin and dextran of 
mol. wt. 70,000 were purchased from Sigma Chemical Company, St. Louis, Missouri, 
USA. Carrier-free Na [125I] was obtained from BARC, Bombay. Concanavalin A 
(Con A) was prepared according to the method of Surolia et al. (1973). All other 
chemicals used were of analytical grade. 
 
Radioiodination of  γ-globulin 
 
Radioiodination of γ-globulin was done by the Chloramine-T method of Hunter (1978) 
using carrier-free Na [125I] . The iodinated protein was separated from free iodide by 
gel filtration on Sephadex G-25. The specific activity of iodinated protein was 
2·2 × 106 cpm/µg. 
 
Preparation of liposome 
 
[125I]-Labelled γ-globulin entrapped unilamellar liposomes were prepared with egg 
lecithin (EL), cholesterol (Chol) and phosphatidylethanolamine (ΡΕ) as described 
earlier (Surolia et al., 1975). 
 
Covalent coupling of dextran to PE-liposome 
 
Covalent coupling of dextran to the available amino groups on PE-liposome was done 
by a modification of the method described for dextran-protein conjugates (Marshall 
and Rabinowitz, 1976). Cyanogen bromide (30–35 mg) was added to a stirred solution 
of dextran (250 mg) in 5 ml of distilled water, adjusted to pH 10·7 with 1 Μ NaOH, 
followed by a second addition of cyanogen bromide (30–35 mg), 30 min later. The pH 
was maintained at 10·7 by 1 Μ NaOH throughout the activation. Thirty minutes after 
the second addition, cyanogen bromide (20–25 mg) was again added and allowed to 
react for another 20 min at pH 10·7. The reaction mixture was then dialysed at 4°C for 
1 h against 0·15 Μ NaCl, pH 9·0, adjusted with Na2CO3. The dialysate was added to 
3–4 ml of liposome preparation containing, entrapped [125I]-γ-globulin and the 
mixture was stirred overnight at 4°C. The excess unreacted dextran was blocked by the 
addition of 0·2 ml of dilute ethanolamine (1:25). After stirring for another 
2 h, the conjugate was purified by gel filtration on Sepharose-6B. 
 
Animal experiments 
 
Male Swiss albino mice (IICB strain) weighing approx. 25–30 g were used throughout 
the experiment. Each pentobarbital anaesthesized mouse received a single intravenous 
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injection of 0·25 ml liposome suspension (1–1·5 mg lipids) containing 3–6 × 104cpm 
entrapped [125I]-γ-globulin. After time intervals of 2·5, 5, 15, 30, 60, and 120 min, 
samples of blood were withdrawn from the femoral artery of groups of three mice. 
Subsequently they were sacrificed and their livers, kidneys, spleens and lungs were 
removed. Each tissue was washed with saline and blotted with filter paper. The whole 
liver was digested with 5 ml of 30 % KOH solution and 2 ml of the liver-digest was 
taken for radio-active counting. Other tissues were digested in 1 ml of 30% KOH 
solution and counted. Radioactivity was measured in a Prias Scintillation gamma 
counter. 
 
 
Results and discussions 
 
We have investigated the effect of dextran conjugation to small unilamellar liposomes 
on the rate of clearance of their entrapped solute contents from the blood and also the 
uptake by different tissues of the injected animals. [125I]-γ-Globulin was taken as the 
entrapped marker. 
 
Dextran-liposome conjugate 
 
The dextran liposome conjugate was freed from any unreacted dextran by gel filtration 
on Sepharose-6B and subsequently characterized by its agglutination by Con A. 
Different amounts of PE (10, 18 and 30 mol%) were taken for liposome preparation 
and were conjugated with the same amount of dextran (250 mg). When all types of 
conjugates were separately agglutinated by Con A followed by centrifugation, the 
radioactivity present in the supernatant fractions was negligible showing thereby that 
the conjugate preparation does not contain any unreacted liposome. This can be 
explained due to the use of excess dextran over the available amino groups on the PE 
liposome. However, as expected the conjugate preparations differ significantly in their 
dextran content and this was monitored by the per cent of total amino groups available 
even after the coupling, as estimated by the titrations of the liposomal PE amino groups 
with trinitrobenzesulphonic acid in the presence of 0·1% Triton X-100 (Torchillin et al., 
1978). In addition, when the purified liposome-dextran conjugate in 6 Μ urea was 
rechromatographed on Sepharose-6B to remove contaminated noncovalent material, if 
any, no peak other than the conjugate was obtained. Therefore, the presence of any 
non-specifically adsorbed dextran on liposomal surface is quite unlikely.
 
Blood clearance and tissue uptake studies 
 
Figure 1 shows the rates of clearance of entrapped protein from the circulation of mice. 
Dextran conjugated PE-liposomes were found to be much more efficient in retaining 
the radioactivity in blood stream compared to control liposomes (PE-liposomes). 
About 80% of the control liposomes are removed from the circulation after 30 min of 
injection, whereas only 50% of the injected dextran-liposomes are cleared during this 
period. The difference in the retention in circulation of dextran-liposome is found to be 
2-fold higher even after 2h of intravenous injection (18% and 8% respectively). 
In another control experiment, mice were injected with 0·25 ml of a mixture of 
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Figure 1. Clearance of different types of liposomes from the circulation of mice. Mice were 
injected with liposomes containing [125I]-γ-globulin (3–6 × 104 cpm). Radioactivity was 
measured in the blood, the volume of which in all the experiments described here was taken as 
2·0ml per 25 g body wt. and was expressed as a percentage of the injected radioactivity 
per total volume of blood. Each point is an average value obtained from three mice. (▲), 
Liposome-PE (control); (●), Liposome-PE (10 mol%)-dextran; (○), liposome-PE (18 mol%)- 
dextran; (Δ), liposome-PE (30 mol%)-dextran. 
 
 
250 mg of dextran (uncoupled) and radio-labelled PE-liposomes (3 ml) and no 
significant effect was observed on the clearance of the latter as compared with PE- 
liposomes alone (data not shown). 
Since the amount of dextran on the surface of liposome may be a determining factor 
for the retention in circulation, varying amounts of PE were taken for the preparation 
of dextran-liposome conjugates. The extent of dextran coupling is proportional to the 
number of free amino groups of PE present on the outer surface of liposomes. Thus an 
increase in the mol % of PE will reflect a corresponding increase in the amount of 
dextran molecules coupled with the PE liposomes. It was observed that the rate of 
disappearance of the conjugated liposome from the circulation decreases as the amount 
of PE in the liposome increases up to a critical concentration of 18 mol%, above which 
the rate of clearance remains unaltered. Therefore, this could be due to saturation of 
dextran binding sites on the surface of liposomes, resulting from a steric hindrance 
caused by the bound dextran molecules. 
Differences in the survival of liposomal encapsulated marker in the circulation 
caused by coupling with dextran should reflect in the extent of uptake by liver and 
spleen. Tissue distribution of liposome entrapped γ-globulin at different time intervals 
is presented in table 1. The amount of radioactive marker taken up by the liver and 
spleen is greater for control liposomes than for dextran liposomes. In both the cases, the 
maximum uptake by the liver occurred 15 min after the administration of liposomes, 
after which there was a gradual decrease in the amount of radioactivity in the liver. This 
may be due to the possible lysosomal degradation of the protein marker in the liver. 
 
Presumably dextran does not cross the cell membrane (Molteni, 1979) which could 
explain why proteins or haptens coupled to dextran remain in circulation for longer 
times. Though there are reports (Richter and Hedin, 1982) of dextran hypersensitivity 
on protracted use in a few patients, the use of clinical grade dextran may considerably 
reduce the chances of such toxicity in most of the individuals. A sensitivity test for 
dextran may be performed to avoid any possible side effect in vivo. However, the 
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optimal molecular size of coupled dextran and its role in diminishing the liposomal 
disappearance from blood remain to be determined. 
Regardless of the mechanism by which dextran promotes the stability of liposome in 
vivo, dextran conjugated liposome should provide an effective means for controlled 
drug release over longer periods. Such controlled release may be of particular 
importance in diseases where the slow release of a drug is essential. 
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